PMID- 29681852
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 9
DP  - 2018
TI  - Genotypic and Phenotypic Factors Influencing Drug Response in Mexican Patients 
      With Type 2 Diabetes Mellitus.
PG  - 320
LID - 10.3389/fphar.2018.00320 [doi]
LID - 320
AB  - The treatment of Type 2 Diabetes Mellitus (T2DM) consists primarily of oral 
      antidiabetic drugs (OADs) that stimulate insulin secretion, such as sulfonylureas 
      (SUs) and reduce hepatic glucose production (e.g., biguanides), among others. The 
      marked inter-individual differences among T2DM patients' response to these drugs 
      have become an issue on prescribing and dosing efficiently. In this study, 
      fourteen polymorphisms selected from Genome-wide association studies (GWAS) were 
      screened in 495 T2DM Mexican patients previously treated with OADs to find the 
      relationship between the presence of these polymorphisms and response to the 
      OADs. Then, a novel association screening method, based on global probabilities, 
      was used to globally characterize important relationships between the drug 
      response to OADs and genetic and clinical parameters, including polymorphisms, 
      patient information, and type of treatment. Two polymorphisms, ABCC8-Ala1369Ser 
      and KCNJ11-Glu23Lys, showed a significant impact on response to SUs. Heterozygous 
      ABCC8-Ala1369Ser variant (A/C) carriers exhibited a higher response to SUs 
      compared to homozygous ABCC8-Ala1369Ser variant (A/A) carriers (p-value = 0.029) 
      and to homozygous wild-type genotypes (C/C) (p-value = 0.012). The homozygous 
      KCNJ11-Glu23Lys variant (C/C) and wild-type (T/T) genotypes had a lower response 
      to SUs compared to heterozygous (C/T) carriers (p-value = 0.039). The screening 
      of OADs response related genetic and clinical factors could help improve the 
      prescribing and dosing of OADs for T2DM patients and thus contribute to the 
      design of personalized treatments.
FAU - Sanchez-Ibarra, Hector E
AU  - Sanchez-Ibarra HE
AD  - Molecular Genetics Laboratory, Vitagenesis, S.A. de C.V., Monterrey, Mexico.
FAU - Reyes-Cortes, Luisa M
AU  - Reyes-Cortes LM
AD  - Molecular Genetics Laboratory, Vitagenesis, S.A. de C.V., Monterrey, Mexico.
FAU - Jiang, Xian-Li
AU  - Jiang XL
AD  - Evolutionary Information Laboratory, Department of Biological Sciences, 
      University of Texas at Dallas, Richardson, TX, United States.
FAU - Luna-Aguirre, Claudia M
AU  - Luna-Aguirre CM
AD  - Molecular Genetics Laboratory, Vitagenesis, S.A. de C.V., Monterrey, Mexico.
FAU - Aguirre-Trevino, Dionicio
AU  - Aguirre-Trevino D
AD  - Molecular Genetics Laboratory, Vitagenesis, S.A. de C.V., Monterrey, Mexico.
FAU - Morales-Alvarado, Ivan A
AU  - Morales-Alvarado IA
AD  - Molecular Genetics Laboratory, Vitagenesis, S.A. de C.V., Monterrey, Mexico.
FAU - Leon-Cachon, Rafael B
AU  - Leon-Cachon RB
AD  - Departamento de Ciencias Basicas, Centro de Diagnostico Molecular y Medicina 
      Personalizada, Vicerrectoria de Ciencias de la Salud, Universidad de Monterrey, 
      Monterrey, Mexico.
FAU - Lavalle-Gonzalez, Fernando
AU  - Lavalle-Gonzalez F
AD  - Servicio de Endocrinologia, Hospital Universitario Dr. Jose E. Gonzalez, 
      Universidad Autonoma de Nuevo Leon, Monterrey, Mexico.
FAU - Morcos, Faruck
AU  - Morcos F
AD  - Evolutionary Information Laboratory, Department of Biological Sciences, 
      University of Texas at Dallas, Richardson, TX, United States.
AD  - Center for Systems Biology, University of Texas at Dallas, Richardson, TX, United 
      States.
FAU - Barrera-Saldana, Hugo A
AU  - Barrera-Saldana HA
AD  - Molecular Genetics Laboratory, Vitagenesis, S.A. de C.V., Monterrey, Mexico.
AD  - Tecnologico de Monterrey, Monterrey, Mexico.
LA  - eng
PT  - Journal Article
DEP - 20180406
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC5898372
OTO - NOTNLM
OT  - Mexican
OT  - biguanides
OT  - diabetes
OT  - direct coupling analysis
OT  - direct information
OT  - pharmacogenetics
OT  - pharmacogenomics
OT  - sulfonylureas
EDAT- 2018/04/24 06:00
MHDA- 2018/04/24 06:01
PMCR- 2018/04/06
CRDT- 2018/04/24 06:00
PHST- 2018/01/19 00:00 [received]
PHST- 2018/03/20 00:00 [accepted]
PHST- 2018/04/24 06:00 [entrez]
PHST- 2018/04/24 06:00 [pubmed]
PHST- 2018/04/24 06:01 [medline]
PHST- 2018/04/06 00:00 [pmc-release]
AID - 10.3389/fphar.2018.00320 [doi]
PST - epublish
SO  - Front Pharmacol. 2018 Apr 6;9:320. doi: 10.3389/fphar.2018.00320. eCollection 
      2018.